SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

$CAW, also known as crow with knife, is trending due to its active community and multichain functionality across $SOL, BSC, $CRO, and $ETH (BASE), with some users suggesting new staking opportunities may be coming. Community members highlight the project's fully circulated supply, deflationary burn mechanism, and partnerships within the crypto space as key factors.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to strong community support and ongoing building efforts, including IRL initiatives and new product teases like KENDU SPICE. Community members express conviction and encourage others to join the movement, emphasizing KENDU's potential to become a major brand. Discussions also highlight the upcoming KENDU Games release and various merchandise offerings.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid speculation of a potential acquisition, especially after Pfizer's recent move in the obesity market, sparking discussions about Viking's value and potential suitors. Community members are debating the company's valuation, comparing its assets to competitors, and analyzing potential buyout scenarios. Discussions also include the impact of potential Medicare/Medicaid coverage on the obesity market and potential partnership.

The Singularity is a visionary project built around the story of ION, a humanoid AI robot who journeys through the quiet ruins of human civilization, guided by a glowing blue butterfly. The project blends narrative, art, and blockchain utility to explore the balance between artificial intelligence and the natural world, symbolizing harmony at the edge of technological singularity. The token serves as the foundation of this ecosystem, enabling community participation, creative expression, and future expansion into interactive experiences. Beyond its story-driven identity, the project aims to create a meaningful digital space where holders gain access to unique content, governance opportunities, and cross-platform collaborations that highlight the synergy of technology and nature. This is more than just a token; it is a gateway to an evolving narrative-driven universe with long-term growth potential.

The Singularity

Singularity Crypto is drawing attention, though community sentiment appears mixed. Discussions revolve around market liquidity and speculation about coordinated pumps and dumps. Some users are critical, while others express enthusiasm with calls to action.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as community members discuss its potential breakout and historical performance relative to Bitcoin. Some traders are pointing to technical indicators and the possibility of a short squeeze, while others remain skeptical, citing past underperformance. Privacy features and potential institutional investment through ETFs are also being mentioned as possible catalysts.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies behind the OG meme, emphasizing its cultural significance and the strength of their collective belief. Community members highlight that $RAGE represents more than just a meme; it's a symbol of unity and a return to the roots of internet culture. The focus is on building a strong community and culture, rather than chasing fleeting trends.

Monero

Monero is gaining traction as community members emphasize its importance as a leading privacy coin, drawing comparisons to what Bitcoin was originally intended to be. Despite some exchanges delisting XMR, discussions highlight Monero's solid use case, adoption in certain markets, and potential for significant growth as privacy becomes more valued in the crypto space. The community believes Monero is undervalued and poised for a substantial move.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

EOSE is trending as investors compare it to PLTR and IREN, anticipating a similar breakout. The company's recent collaboration and supply agreements are fueling optimism, with community members citing a large commercial pipeline. Discussions revolve around key resistance levels and potential for significant growth in the energy storage sector, particularly related to AI and hyperscalers.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending due to the ongoing debate around the ACA subsidies and its potential impact on the company's future. The community is discussing potential market share shifts, the possibility of an ACA extension, and the stock's overall volatility. Some traders express bullish sentiments, while others remain cautious due to the uncertainty surrounding healthcare legislation and recent sector-wide pressures.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is trending as community members discuss its potential, with some pointing to user growth surpassing Solana and Ethereum as a possible catalyst. Bullish sentiment is evident, with many anticipating a significant price increase and viewing dips as buying opportunities. Discussions also highlight NEAR's developments in AI and cross-chain interoperability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) released its earnings results on Wednesday. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by...

Lexeo Therapeutics (NASDAQ:LXEO) Earns Buy Rating from Chardan Capital

Chardan Capital reiterated a "buy" rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Wednesday...

Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High?

The consensus price target hints at a 108.2% upside potential for Lexeo Therapeutics, Inc. (LXEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Lexeo Therapeutics shares rose to an 11-month high on Tuesday following a series of analyst upgrades that have rekindled investor interest in the biotech’s gene therapy LX2006 for heart problems associated with Friedreich’s ataxia.The rally came after Lexeo said the U.S. Food and Drug Administration has expressed willingness to consider an accelerated approval pathway for LX2006. Such a move would allow Lexeo to combine data from its current early-stage studies with results from an ongoing pivotal trial, potentially reducing the time to commercialization.Leerink Partners lifted the firm’s price target to $20 from $9 and reiterated an 'Outperform' rating, noting that the FDA’s willingness to pool data from the ongoing Phase I/II SUNRISE-FA and pivotal studies represents “regulatory flexibility and a relatively straightforward path to approval.”&nbsp;The brokerage stated that the FDA’s decision to assess the left ventricular mass index (LVMI), the therapy’s key cardiac endpoint, earlier than planned could accelerate timelines. Additionally, further clinical data show dose-dependent, durable LVMI reductions and clean safety profiles.H.C. Wainwright raised its price target to $15 from $9 and maintained a 'Buy' rating, saying the FDA feedback improves the probability of approval to 50% from 40%. The firm also advanced its expected commercial launch to 2028 from 2030, pointing to a faster and smaller pivotal trial.Chardan followed with an increase to $17 from $15, also keeping a 'Buy' rating. The firm stated that the FDA’s decision to allow the pooling of Phase I/II and pivotal data supports the potential for accelerated approval, while updated results showed “sustained and dose-dependent improvements” in cardiac measures.The bullish revisions followed Lexeo’s announcement that the FDA was open to a Biologics License Application (BLA) that combines data from its Phase I/II studies with new pivotal data to support accelerated approval. The agency also agreed to assess LVMI improvements earlier than 12 months.Interim results from the ongoing LX2006 trials showed encouraging efficacy, with participants who had abnormal heart mass at baseline achieving an average 18% reduction in LVMI at six months and 23% at 12 months, well above the FDA’s 10% improvement threshold.&nbsp;Neurological function also improved as measured by patients' scores on the modified Friedreich Ataxia Rating Scale (mFARS) and reductions in cardiac biomarkers, including troponin I and lateral wall thickness. The therapy was well tolerated, with no serious adverse events. The company plans to initiate the pivotal study in the first half of 2026, pending completion of final protocol and manufacturing comparability reviews.LX2006 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations, among others, and is part of the FDA’s CMC Development and Readiness Pilot (CDRP) program. The company expects the therapy to advance into its pivotal stage within the next year and believes the new framework could bring approval two years earlier than previously projected.On Stocktwits, retail sentiment for Lexeo was ‘extremely bullish’ amid a 6,200% surge in 24-hour message volume.One user called the FDA update a major win but warned of a dilution risk, noting that Lexeo’s $75 million shelf registration and recent $80 million private placement could lead to a share sale if the stock continues to rise. They said it’s a typical biotech setup with big news, big move, then dilution.<stembedurl>https://stocktwits.com/Jamesnewbie/message/631275401</stembedurl>Another user took a more upbeat tone, suggesting a rapid rally ahead, stating that a swift move to $20 could be on the way.&nbsp;<stembedurl>https://stocktwits.com/kpop1/message/631309344</stembedurl><a href="https://stocktwits.com/symbol/LXEO">Lexeo’s stock</a> has risen 27% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Lexeo’s stock (LXEO) has risen 27% so far in 2025. (Photo credit: Getty Images)

Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In

Analysts raised price targets and boosted approval odds after the FDA signaled support for a faster review process, citing strong safety and efficacy data in early trials of Lexeo’s treatment for Friedreich’s ataxia–related heart disease.

Equity

Lexeo Therapeutics (LXEO) announced on Tuesday that the company is considering a smaller pivotal study for LX2006 in the treatment of Friedreich's ataxia (FA) cardiomyopathy, scheduled to begin in the first half of 2026, pending finalization of the study protocol.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.lexeotx.com/news-releases/news-release-details/lexeo-therapeutics-announces-progress-fda-discussions">data</a> from the planned pivotal study will be pooled with data from the ongoing Phase I/II studies of LX2006 to support an approval application to the U.S. Food and Drug Administration for the therapy, the company stated after discussions with the agency.Lexeo will submit enhanced manufacturing comparability data and meet an additional nonclinical requirement before the initiation of the planned pivotal study to enable pooling, the company added.Lexeo is continuing to engage with the agency regarding the protocol of the pivotal study, it stated, adding that it believes this regulatory feedback has the potential to reduce the size and duration of the planned pivotal study. The company is also optimistic that the feedback may accelerate the overall timeline to an application submission.Updated interim clinical data from both ongoing Phase I/II studies of LX2006 show sustained or deepening improvements in the majority of participants across both cardiac and neurologic measures of Friedreich’s ataxia, the company said.FA cardiomyopathy is the leading cause of death in individuals with Friedreich’s ataxia (FA), a rare, inherited neurodegenerative disorder causing progressive damage to the nervous system, leading to impaired balance, muscle coordination, and sensory loss, often beginning in childhood. It is estimated to affect approximately 5,000 people in the U.S.Shares of the company rallied 24% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LXEO">LXEO stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1368/120;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_9_19_18_AM_png_3d23b7c692.webp" alt="LXEO's Sentiment Meter and Message Volume as of 9:19 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1368" height="120"><figcaption>LXEO's Sentiment Meter and Message Volume as of 9:19 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>LXEO stock has risen 22% this year and but fallen by approximately 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-reportedly-slashes-workforce-at-its-us-wegovy-manufacturing-plant/ch6PBqJR3WD">Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process

The company stated that data from a planned pivotal study will be pooled with data from the ongoing Phase I/II studies of LX2006 to support an approval application to the U.S. Food and Drug Administration for the therapy. 

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Shares of clinical-stage genetic medicine company Lexeo Therapeutics, Inc. soared over 50% on Monday, marking their best day on record. The rally extended into after-hours trading following the company's latest quarterly results, which largely pleased investors.Lexeo specializes in therapies for hereditary and acquired diseases, with a focus on genetically defined cardiovascular conditions and a subset of Alzheimer's disease.&nbsp;Its pipeline includes LX2006 for treating Friedreich's ataxia cardiomyopathy and LX1001 for APOE4 homozygous Alzheimer's patients.According to Stocktwits data, the company reported an adjusted fourth-quarter loss of $0.78 per share, beating expectations for a $0.81 loss. The early-stage biotech firm is still in a pre-revenue stage.CEO R. Nolan Townsend highlighted regulatory progress on LX2006, noting ongoing collaboration with the FDA for an accelerated approval pathway.&nbsp;He also announced promising early safety data for LX2020, a treatment for arrhythmogenic cardiomyopathy (PKP2-ACM).&nbsp;The company expects to share additional clinical updates later in 2025, with the second cohort of a Phase 1/2 trial now fully enrolled.Despite the stock's sharp rally, Leerink lowered its price target from $19 to $18, which still implies a potential fourfold gain from current levels.&nbsp;The research firm remains bullish, citing positive registrational design elements in the LX2006 pivotal trial and interim data for LX2020.Lexeo ended 2024 with $128.5 million in cash and investments, which management believes will sustain operations into 2027.On Stocktwits, Lexeo's following surged 13% — the largest jump among biotech stocks.&nbsp;The stock, however, remains down over 39% year-to-date, with short interest creeping up from 6.2% to 7.3%.Traders on Stocktwits are watching technical patterns closely.&nbsp;"Nice breakout. I could see this running for a while," one user noted.<stembedurl>https://stocktwits.com/Sillyspuh/message/609105298</stembedurl>Another speculated that a cup-and-handle formation was forming.<stembedurl>https://stocktwits.com/Marcobucks/message/609063542</stembedurl>According to Koyfin, seven Wall Street analysts cover Lexeo. Four rate it a 'buy,' while three assign a 'strong buy' or equivalent rating.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw?

The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss.  

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ('Satellos' or the 'Company'), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle...

Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data

Shares of Lexeo Therapeutics (NASDAQ: LXEO) lost 26% on Monday after it reported positive interim data from two cohorts of the phase I/II SUNRISE-FA study evaluating LX2006, an investigational gene...

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Lexeo Therapeutics Inc.

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.33	--	--	N/A
Q3 '25	-$0.52	-$0.33	36.54%	BEAT
Q2 '25	-$0.68	-$0.60	11.68%	BEAT
Q1 '25	-$0.78	-$0.99	-26.38%	MISSED
Q4 '24	-$0.81	-$0.78	3.36%	BEAT

LXEO
Lexeo Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest LXEO News

LXEOLexeo Therapeutics Inc.